Disease Areas


COPD is one of the most frequent respiratory diseases in Germany and worldwide and is projected to rank fifth in 2020 in burden of disease worldwide. Smoking is the most important risk factor for COPD.
In view of limited health care resources, decision makers are in need of representative and valid data concerning costs and outcomes of COPD. Such questions are particularly relevant since COPD is a chronic and progressive disease with a high comorbidity burden which results in multiple treatments and interactions between treatments. The assessment of health care provision, resource utilization and patient-relevant outcomes in COPD serves as a basis for efficient patient management strategies which add value to individuals concerned and society as a whole.

Research questions and projects:

  • Analyzing cost-of-illness and health-related quality of life in patients with COPD stratified by disease stages and comorbidity status based on data from COPD cohorts, population based studies and routine practice data.
  • Analyzing quality of medical care of patients with COPD with focus on adherence to national COPD treatment guidelines and disease management programs.
  • Cost-effectiveness modelling of COPD interventions, e.g. smoking cessation.
  • Validation of COPD cost-effectiveness models (initiated by Erasmus  University Rotterdam)
  • Further development of target group specific disease management approaches based on quality of life data from COPD patients and exploring the potential for quality of life-oriented patient management in routine care.

Co-operation partners:


  • The contribution of symptoms and comorbidities to the economic impact of COPD: an analysis of the German COSYCONET cohort. International Journal of COPD 2017
  • Relationship of hyperlipidemia to comorbidities and lung function in COPD: results of the COSYCONET cohort. Plos One 2017
  • Costs and Health-Related Quality of Life in Alpha-1-Antitrypsin Deficient COPD Patients. Respiratory Research 2017
  • Transfer factor for carbon monoxide in patients with COPD and diabetes: Results from the German COSYCONET cohort. Respiratory Research 2017
  • External validation of health economic decision models for chronic obstructive pulmonary disease (COPD): report of the third COPD modeling meeting. Value in Health 2017
  • Systematic analysis of self-reported comorbidities in large cohort studies - a novel stepwise approach by evaluation of medication. Plos One 2016
  • Peripheral Artery Disease and its Clinical Relevance in Patients with COPD in the COSYCONET Study. American Journal of Respiratory and Critical Care Medicine 2016
  • Impact of chronic ischemic heart disease on the health care costs of COPD patients - An analysis of German claims data. Respiratory Medicine 2016
  • Relative impact of COPD and comorbidities on generic health-related quality of life: a pooled analysis of the COSYCONET patient cohort and control subjects from the KORA and SHIP studies. Respiratory Research 2016
  • Patient heterogeneity in cost-effectiveness models for chronic obstructive pulmonary disease (COPD): are current models suitable to evaluate personalized medicine? Value in Health 2016
  • Assessing health-related quality of life in COPD: comparing generic and disease-specific instruments with focus on comorbidities. BMC Pulmonary Medicine 2016
  • Direct and indirect costs of COPD and its comorbidities: Results from the German COSYCONET study. Respiratory Medicine 2016
  • Comorbid Influences on Generic Health-Related Quality of Life in COPD: a Systematic Review. Plos One 2015
  • Excess costs of comorbidities in chronic obstructive pulmonary disease: a systematic review. Plos One 2015
  • Cost-effectiveness models for chronic obstructive pulmonary disease: cross-model comparison of hypothetical treatment scenarios. Value Health 2014
  • Health-related quality of life and chronic obstructive pulmonary disease in early stages - longitudinal results from the population-based KORA cohort in a working age population. BMC Pulmonary Medicine 2014
  • [Costs of Illness for Asthma and COPD in Adults in Germany.] Gesundheitswesen 2013
  • A lifetime Markov model for the economic evaluation of chronic obstructive pulmonary disease. Pharmacoecnomics 2012
  • Direct medical cost of COPD – an excess cost approach based on two population-based studies. Respiratory Medicine 2012
  • Health-related quality of life in patients with severe COPD hospitalized for exacerbations - comparing EQ-5D, SF-12 and SGRQ. Health and Quality of Life Outcomes 2010

back to Junior research group